EPICS: Global Perspectives in Lung Cancer – WCLC and ESMO 2021
Expert perspectives and strategic insights on the latest therapeutic developments and translational research coming out of ESMO and WCLC 2021 regarding lung cancer treatment.
FACULTY CHAIR
Corey Langer, MD, FACP
University of Pennsylvania, Philadelphia, PA, US
Faculty Members
Benjamin Besse, MD, PhD
Institute Gustave Roussy, Villejuif, France
Enriqueta Felip, MD, PhD
Vall d’Hebron University Hospital, Barcelona, Spain
Nasser Hanna, MD
Indiana University School of Medicine, Indianapolis, IN, US
Solange Peters, MD, PhD
University Hospital of Lausanne, Switzerland
Lynette Sholl, MD
Harvard Medical School, Boston, MA, US
David Spigel, MD
Sarah Cannon Research Institute, Nashville, TN, US
David Jablons, MD
University of California, San Francisco, CA, US
Natasha Leighl, BSc, MMSc, MD
Princess Margaret Cancer, Toronto, CA
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
- Immunotherapy in Stage I–III NSCLC
- Immunotherapy in Metastatic NSCLC and Subsequent Therapy
- EGFR (Common Mutations): Resectable and Metastatic
- EGFR (Less Common Mutations, Including Exon 20 Insertions)
- Other Targets in NSCLC and SCLC
